ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $280 | -99.9% | 2,995 | +69.1% | 0.03% | +86.7% |
| Q1 2022 | $208,000 | -56.6% | 1,771 | -50.2% | 0.02% | -69.4% |
| Q4 2021 | $479,000 | +116.7% | 3,558 | +111.5% | 0.05% | +133.3% |
| Q2 2021 | $221,000 | -19.9% | 1,682 | -5.9% | 0.02% | -55.3% |
| Q3 2020 | $276,000 | -56.3% | 1,787 | -67.4% | 0.05% | +27.0% |
| Q2 2019 | $631,000 | +173.2% | 5,483 | +179.2% | 0.04% | +184.6% |
| Q1 2019 | $231,000 | +1.8% | 1,964 | -43.5% | 0.01% | +8.3% |
| Q1 2018 | $227,000 | – | 3,478 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
| RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
| Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
| BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
| Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
| Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
| Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
| Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
| Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
| Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |